VEGF (vascular endothelial growth factor) is the master regulator of blood vessel growth. However, it displayed substantial limitations when delivered as a single gene to restore blood flow in ischaemic conditions. Indeed, uncontrolled VEGF expression can easily induce aberrant vascular structures, and shortterm expression leads to unstable vessels. Targeting the second stage of the angiogenic process, i.e. vascular maturation, is an attractive strategy to induce stable and functional vessels for therapeutic angiogenesis. The present review discusses the limitations of VEGF-based gene therapy, briefly summarizes the current knowledge of the molecular and cellular regulation of vascular maturation, and describes recent pre-clinical evidence on how the maturation stage could be targeted to achieve therapeutic angiogenesis.
Introduction
The growth of new blood vessels (angiogenesis) is a fundamental process to allow tissue repair and regeneration and plays also a crucial role in many pathological conditions, such as cancer, inflammation and ischaemia. In particular, therapeutic angiogenesis, i.e. the stimulation of vascular growth by the delivery of specific growth factors, is an attractive strategy to restore blood flow in chronically ischaemic tissue. VEGF (vascular endothelial growth factor) is the master regulator of angiogenesis in both development and postnatal life. However, angiogenesis is a complex multi-step process that requires the temporal and spatial co-ordination of different factors and cell types. Endothelial cells proliferate and migrate in response to VEGF gradients to form new tubular structures. Subsequently, the maturation of new blood vessels requires the recruitment of mural cells (pericytes or smooth muscle cells) and the deposition of a basal lamina [1] . The maturation stage is crucial to ensure the return to quiescence of the activated endothelium, as well as the persistence and the functionality of the new vascular structures. Therefore an understanding of the cellular and molecular cross-talk during the different stages of vascular growth is crucial to design therapeutic strategies that are both safe and effective.
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disappointing [2] , and, although VEGF gene delivery was safe, it did not generate sufficient angiogenesis to correct the underlying ischaemia. Retrospective analyses have uncovered several factors that had not been adequately taken into consideration in designing the first clinical trials and that could account for the therapeutic results [3] . Of these, we focus on two limitations of VEGF-based gene therapy that arise from biological properties of VEGF itself, namely the need to control its dose distribution in vivo and the requirement for prolonged expression.
Several lines of evidence suggest that VEGF gene delivery has a very narrow therapeutic window in vivo: low doses have no or little angiogenic effects, whereas higher doses rapidly become unsafe, inducing vessels that frequently display morphological and functional abnormalities. Exogenous VEGF administration during embryonic vasculogenesis results in profoundly altered development of vessels with large lumens [4] . Furthermore, transgenic mice overexpressing VEGF in the skin, as well as in the heart and liver, display malformed leaky vessels with unusually large and irregular lumens [5, 6] . The induction of vascular tumours (haemangiomas) as a consequence of uncontrolled VEGF expression was also reported in skeletal muscle [7] and in the myocardium [8] after the delivery of retrovirally transduced myoblasts. Adenoviral overexpression of VEGF in the skin, fat, heart and skeletal muscle of mice caused the formation of enlarged, thin-walled, pericyte-poor vessels, as well as multi-lumenized glomeruloid structures that resembled tumour-associated vascular malformations [9, 10] . Finally, angioma growth was observed in infarcted rat hearts after the injection of a VEGFencoding plasmid [11] .
Previous work from our group has carefully investigated the dose-dependent effects of VEGF in both normal and ischaemic skeletal muscle [12, 13] . These results indicate that VEGF does not have an intrinsically narrow dose-response curve. However, VEGF induces normal or aberrant angiogenesis depending on its amount in the microenvironment around each producing cell, and not on its total dose, as it remains localized in the extracellular matrix [14] . Therefore direct in vivo gene therapy approaches, which generate heterogeneous expression levels around each transduced cell, lead to a waste of the therapeutic window [14] .
Duration of expression is another crucial point to be considered when delivering VEGF for therapeutic angiogenesis. On one hand, it is desirable to avoid longterm expression of a potent growth factor such as VEGF, but on the other, too brief expression is ineffective. In a transgenic system of conditional switching of VEGF expression, it has been shown that VEGF production for approximately 2 weeks leads to unstable vessels that promptly regress as soon as the angiogenic stimulus is stopped. However, if expression was prolonged for at least 4 weeks, the new vessels matured and persisted indefinitely after VEGF withdrawal [5] . VEGF-dependence of newly induced vessels has been demonstrated also by injecting inducible AAVs (adeno-associated vectors) in skeletal muscle, confirming that sustained VEGF expression for at least 1 month is needed to induce the formation of stable vessels [15] . Furthermore, abrogation of VEGF signalling with a recombinant receptor-body (VEGF-Trap) did not cause regression of new vessels only 4 weeks after implantation of VEGF-expressing myoblasts in skeletal muscle. Interestingly, aberrant vessels induced by high VEGF levels never became VEGF-independent [12] .
The need for at least 4 weeks of sustained VEGF expression in order to generate stable vessels is a challenge for the use of short-term gene-delivery systems, such as plasmids and adenoviral vectors, for therapeutic angiogenesis.
Mechanisms of vascular maturation
Vascular maturation, which involves the induction of endothelial quiescence and protection against VEGF withdrawal, requires a tight co-ordination of different cell types, including endothelial cells, smooth muscle cells/pericytes and recently described populations of myeloid cells [16] ( Figure 1) . Nascent endothelial tubes are coated by pericytes. During vessel sprouting, pericytes are recruited by PDGF-BB (platelet-derived growth factor BB) produced by the migrating tip cell. Genetic studies revealed that mice lacking PDGF-BB or PDGFRβ (platelet-derived growth factor receptor β) genes display vascular abnormalities, formation of microaneurysms and bleeding [17, 18] . Pericyte deficiency in mice lacking the NG2 (nerve/glial antigen-2) proteoglycan results in immature tumour vessels and impaired basal lamina assembly [19] .
The association between endothelium and pericytes renders new vessels independent of continued VEGF expression, as demonstrated in the vascularization of the neonatal retina as well as in tumours [20, 21] . In diabetic retinopathy, excessive VEGF production leads to the formation of pericyte-poor and leaky vessels, resulting in blindness [22] . Continuous uncontrolled VEGF overexpression in skeletal muscle, by retrovirally transduced myoblasts, also induced aberrant vessels that were not covered by pericytes and failed to stabilize, remaining dependent on VEGF signalling for survival [12] .
Pericyte-endothelium cross-talk
Pericytes exert their regulatory function on endothelial cells through both cell-cell contact and secreted signals. In particular, the role of the TGFβ (transforming growth factor β) and angiopoietin signalling pathways are the best understood.
TGFβ1 regulates endothelial cell proliferation and differentiation through the ALK1 and ALK5 (activin receptor-like kinase 1 and 5) receptors [23] . Both endothelial cells and pericytes produce TGFβ1 in an inactive form. Only when cell-cell contact is established does the protein undergo the cleavage of the latency-associated peptide by plasmin and become activated [24] . TGFβ1 promotes vessel stabilization by inhibiting the proliferation and migration of endothelial cells and by stimulating mural cell differentiation [25] . Furthermore, it has a direct stimulatory effect on the synthesis and deposition of extracellular matrix components [23] .
Angiopoietins are the ligands for the endothelium-specific tyrosine kinase receptor Tie2 and exert fundamental functions in both the induction and the maturation stages of vascular growth. Ang1 (angiopoietin 1) is expressed by pericytes and has been shown to inhibit vascular permeability in the skin, in tumours and in an in vitro model of the blood-brain barrier by acting as an agonist for the Tie2 receptor [23] . Furthermore, Ang1 acts as a survival signal for endothelial cells [26] and also promotes vascular stabilization by further facilitating pericyte recruitment [27] .
Ang2 (angiopoietin 2) is secreted mainly by endothelial cells at sites of active angiogenesis and is a partial agonist of the Tie2 receptor, which makes its actions context-dependent. In the presence of VEGF, Ang2 promotes sprouting of new blood vessels and remodelling of the vasculature, since it induces the dissociation of pericytes from endothelial cells. In the quiescent vasculature, where Tie2 is constitutively activated by a basal Ang1 expression, Ang2 acts as a functional antagonist of Ang1, binding preferentially to Tie2 without inducing signal transduction and therefore destabilizing mature vessels [28] . The vessel-destabilizing effect of Ang2 has been also demonstrated after transgenic overexpression of Ang2 in a normal retina [29] .
Myeloid accessory cells
Previous studies have revealed an intriguing role for recruited bone-marrow-derived circulating cells in promoting both endothelial sprouting and the stabilization of newly formed vessels [30] (Figure 1B) . In sites of active angiogenesis, VEGF expression drives the recruitment of a population of bonemarrow-derived CXCR4 (CXC chemokine receptor 4)-positive myeloid cells, which are not incorporated into newly formed vessels, but rather acquire a perivascular position and are retained through SDF-1 (stromal-cell-derived factor 1)/CXCR4 signalling. These cells synergistically contribute to the formation of new blood vessels through the secretion of pro-angiogenic factors and the prevention of their recruitment significantly inhibits neovascularization [31, 32] .
Further investigations demonstrated a role for another population of bone-marrow-recruited cells in the process of vascular maturation. Zacchigna et al. [33] demonstrated that cells infiltrating the site of VEGF 165 -induced angiogenesis in skeletal muscle are mainly CD11b + cells co-expressing the VEGF and semaphorin-3A receptor NRP1 (neuropilin-1), and named them NEM (NRP1-expressing mononuclear) cells. NEM cells were shown to promote vessel maturation through the secretion of different paracrine factors, notably Ang1, TGFβ and PBGF-BB [33] . Therefore the authors proposed a model in which mature vessel formation relies on the occurrence of two events: the activation of endothelial cells, through the canonical VEGF pathway, and the recruitment of bone-marrow-derived cells through the NRP1 receptor. These cells in turn facilitate pericyte or SMC (smooth muscle cell) recruitment to the new vessels by PDGF-BB production [33] .
Vascular maturation as a therapeutic target
Targeting vascular maturation is an attractive strategy to overcome VEGF limitations that became evident in the first generation of clinical trials. The complexity and heterogeneity of factors involved in vascular maturation, described above, suggest different strategies to target this process. To date, investigations have addressed approaches acting either directly on endothelial cell receptors, for example through the co-delivery of Ang1, or indirectly through the recruitment of pericytes by PDGF-BB codelivery.
Systemic administration of Ang1 through intravenous adenoviral delivery has been shown to protect adult vasculature from the lethal vascular leakage induced by systemic VEGF expression [34] . Local co-expression of VEGF and Ang1 has been described to reduce VEGFinduced leakage also in rat hindlimb ischaemia [35] and in normal rat muscle 3 months after AAV injection [36] . Moreover, adenoviral delivery of VEGF and Ang1 induced vessels that were more mature and persisted after 4 weeks, whereas the effect induced by VEGF alone disappeared at the same time point [37] . Although these results clearly demonstrate the role of Ang1 in preventing VEGF-associated oedema, whether Ang1 co-expression might correct the development of aberrant angioma-like structures caused by uncontrolled VEGF levels has not been investigated.
The approach of co-delivering PDGF-BB is based on the rationale that increasing the recruitment of pericytes could provide a comprehensive stimulation of several pathways in a co-ordinated fashion, thereby better reflecting the physiological process. Delivery of recombinant VEGF and PDGF-BB proteins from a polymeric biomaterial has been shown to induce larger and more mature vessels compared with VEGF alone subcutaneously and in ischaemic skeletal muscle [38] . The combination of recombinant PDGF-BB with FGF-2 (fibroblast growth factor-2) has been reported to increase vascular stabilization in the mouse cornea and in rat and rabbit hindlimb ischaemia [39] . However, the combination of PDGF-BB was found not to correct VEGFinduced abnormalities in the cornea and was therefore not pursued further in the more clinically relevant muscle tissue.
Co-delivery of the VEGF and PDGF-BB genes to ischaemic muscle and myocardium by venous retroinfusion of AAV vectors has recently been found to significantly improve the effects of a low VEGF vector dose, in terms of both perfusion and collateral arteriogenesis [40] . Korpisalo et al. [41] studied the effects of VEGF and PDGF-BB co-expression in skeletal muscle by co-delivering two separate adenoviral vectors. They found that the combination of VEGF and PDGF-BB did not significantly increase angiogenesis and failed to reduce VEGF-induced acute oedema 6 days after delivery. In addition, vascular structures induced by the combination of the two viruses showed an impaired mural cell coverage, since pericytes were recruited away from the vascular structures, probably due to the generation of discordant gradients from the two separate vectors. Nevertheless, vessels induced by coexpression persisted longer than those induced by VEGF alone, through pericyte-independent paracrine signals from recruited myeloid cells [41] . These results underline the importance of a proper co-localization of VEGF and PDGF-BB gradients in target tissue in order to stimulate physiological angiogenesis. In fact, using myoblast-mediated gene transfer, we recently found that only VEGF and PDGF-BB co-expression from a single retroviral bicistronic vector, which ensures the generation of coincidential factor gradients around each producing cell in vivo, completely prevented aberrant angiogenesis induced by uncontrolled VEGF levels and induced homogeneous mature capillary networks instead (A. Banfi, G. von Degenfeld, R. GianniBarrera, M.J. Merchant, D.M. McDonald and H.M. Blau, unpublished work). Furthermore, in the same system, we also recently found that PDGF-BB co-expression accelerated stabilization of vessels induced by heterogeneous VEGF levels, so that 50% of new vessels were already VEGFindependent after 2 weeks, whereas none was stable when VEGF was expressed alone (S. Reginato, E. Groppa, R. Gianni-Barrera, M. Herberer and A. Banfi, unpublished work).
Conclusions
The increasing understanding of the biological mechanisms that regulate blood vessels growth and maturation highlights the complexity of molecular and cellular interactions taking place within the angiogenic microenvironment. Therefore targeting both vascular induction and maturation could provide a promising strategy to overcome some limitations related to the use of VEGF as a single factor in gene-delivery approaches for therapeutic angiogenesis.
However, the heterogeneity of delivery systems, of functional readouts and of target tissues considered so far in promoting vascular maturation, generated sometimes unclear or contradictory results. A systematic determination of both efficacy and safety of specific combinations of factors in clinically relevant target tissues, such as skeletal muscle for the treatment of peripheral artery diseases, would greatly benefit the rational design of novel therapeutic angiogenesis strategies.
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